Invest in Digital Health technology with EIS tax relief: Apply for Suisse Life Science Group, the Digital Biological Intelligence company specialising in Personalised Age Management and Ultra-Wellness with the most advanced lifestyle technology.


Imagine a future in which you age, but without the diseases your parents had. A future in which it doesn’t hurt to grow old. At Suisse Life Science, we design lifestyle solutions that prevent, halt, or reverse diseases of ageing.

Research shows that up to 75% of our ageing can be mediated by lifestyle.
Suisse Life Science's my iDDNA® core technology goes above and beyond any existing age management approach creating a real-time, dynamic map of our genetic predispositions and risks (DNA-connections), and genetic and metabolic associations with nutrients, metabolites, environment and lifestyle. It's like Google for your Health & Wellness. Suisse Life Science's middleware technology allows consumers to get true, personalised age management without need of a doctor, practitioners to introduce simplified genomics, lifestyle medicine and digital health in their businesses and DNA testing companies to move from the clinical approach to a responsive, customer-centric digital health seamlessly integrated in the consumer lifestyle.

As an ambitious technology company, we work exclusively with investors that share our passion and vision. We want to work with individuals who bring additional value aside from funding, who have ideas and enthusiasm for a new digital age, who are flexible, fast and results-oriented.
Please note that Suisse Life Science Group will review every application individually and get back to you with additional questions in case you are qualified.


invest digital health UK

In 2016, analysts reported that the global wellness economy reached $3.7 trillion and growth is expected to accelerate by 17% in the next five years*


Access to the information and documents on this portion of the website is restricted for regulatory reasons. We request that you complete all fields below in order to access this information. This personal data will not be retained by us and will be requested of you each time you seek to access this restricted information. It must be true and accurate. The information to which this gatepost gives access is exclusively intended for persons who are not residents of the United States and who are not physically present in the United States. This information does not constitute an offer, or an invitation to purchase, securities of Suisse Life Science Group plc in the United States, Canada, Australia or Japan or in any other jurisdiction in which such offer or invitation is not authorized or to any person to whom it is unlawful to make such offer or solicitation. Potential users of this information are requested to inform themselves about and to observe any such restrictions. Suisse Life Science Group plc’s securities have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. There will be no public offering of the securities in the United States.

From the dropdown menu below, please select your country of residence and the country from which you are viewing this website.
Please note: Your application is non-binding for both parties.

Invest in Personalised Digital Health
Please tick the Terms of Use check box for acceptance.
By signing up I agree to Suisse Life Science Terms of Use
You're accepting Suisse Life Science's Terms and Service and Privacy Policy under the GDPR. We care about your privacy: you can withdraw your consent at any time accessing the link on our Privacy Policy or writing to GIVE CONSENT
invest digital health UK 2 EXCLUSIVE BROKER
Amio Wealth Limited
3-6 Kenrick Place, London, W1U 6HD

+44 20 3307 1250

News & Press